James Kyranos

Vice President, Technical Operations at Orionis Biosciences

James Kyranos has extensive experience in the life sciences and pharmaceutical industry. James started their career as a Unit Manager and Senior Consultant at Arthur D. Little Inc in 1989. James then became the Director of Analytical Chemistry at Biodevelopment Laboratories, where they were responsible for the profitable bioanalytical business unit.

In 1995, Kyranos joined ArQule, Inc as a Vice President of Chemical Technologies, where they successfully managed the scientific and business operations of the independent pharmaceutical discovery unit. James oversaw multi-year external alliances and generated high double-digit net profits to support internal drug discovery programs.

In 2006, Kyranos moved on to become the Vice President of Pre-Clinical Development at Wolfe Laboratories, Inc. James directed all scientific staff and technical operations, implementing operational strategies for growth and profitability.

From 2008 to 2016, Kyranos worked at FORMA Therapeutics, Inc. as the Vice President of Chemical Technologies. James developed an integrated and competitive drug discovery technology platform, managed strategic alliances, and oversaw various operations for oncology drug discovery and development.

Most recently, Kyranos served as the Vice President of Technical Operations at Orionis Biosciences since 2016. James played a key role in pioneering technological innovations in genome-scale drug discovery and developing novel therapeutics for cancer and other diseases.

Overall, Kyranos has a proven track record of leadership and expertise in various roles within the life sciences and pharmaceutical industry.

James Kyranos has a strong education background in the field of Chemistry. James earned their Bachelor of Arts degree in Chemistry and Biology from Boston University, studying there from 1979 to 1983. James continued to pursue their academic career and obtained a Ph.D. in Chemistry from Northeastern University, where they studied from 1983 to 1989.

Links

Previous companies

FORMA Therapeutics logo